320581-97-3

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 75-44-5 phosgene 
• 279236-54-3 tert-butyl 4-(azidocarbonyl)piperidine-1-carboxylate 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 503-38-8 trichloromethyl chloroformate 

Downstream Products

• 1380495-31-7 tert-butyl 4-({[(1R)-1-(4-fluorophenyl)-2-methylpropyl]-carbamoyl}amino)piperidine-1-carboxylate 
• 1380495-33-9 1-[(1R)-1-(4-fuorophenyl)-2-methylpropyl]-3-[1-(2-phenylethyl)piperidin-4-yl]urea oxalate 
• 1428476-67-8 (R)-tert-butyl 4-(6-(2-methylallyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)piperidine-1-carboxylate 
• 1330061-99-8 C₁₇H₂₆N₄O₆S 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

The present disclosure relates to compounds according to Formula (I), treating diseases.

Asymmetric methallylation of ketones catalyzed by a highly active organocatalyst 3,3′-F2-BINOL

(S)-3,3′-F2-BINOL has been synthesized for the first time and demonstrated as a highly active organocatalyst for asymmetric methallylation of ketones. Up to 98:2 enantioselectivity and 99% yield were obtained with 5 mol % catalyst loading. The

Synthesis and pharmacological evaluation of 2-(1-alkylpiperidin-4-yl)-N- [(1R)-1-(4-fluorophenyl)-2-methylpropyl]acetamide derivatives as novel antihypertensive agents

We synthesized and evaluated the inhibitory activity of a series of 2-(1-alkylpiperidin-4-yl)-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]acetamide derivatives against T-type Ca2+ channels. Structure-activity relationship studies revealed that th

PROLINE UREA CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION

Compounds of the formulae (I) and (II) are disclosed. The compounds are CCRl antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

Constrained compounds as CGRP-receptor antagonists

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.